|
|
| View previous topic :: View next topic |
| Author |
Message |
agate
Site Admin
Joined: 17 May 2006
Posts: 5694
Location: Oregon
|
 Posted: Tue Mar 26, 2013 6:09 pm Post subject: (AAN) CCSVI & MS: Changes in treatment patterns... |
 |
|
Presented at the annual AAN conference in San Diego, March 16-23, 2013:
| Quote: |
[P05.183] Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis: Changes in Treatment Patterns and Opinions in a Province-Wide Study
Luanne Metz, Calgary, AB, Canada, Ruth-Ann Marrie, Winnipeg, MB, Canada, Katayoun Alikhani, Calgary, AB, Canada, Gregg Blevins, Edmonton, AB, Canada, Jacqueline Bakker, Red Deer, AB, Canada, Larry Svenson, Edmonton, AB, Canada, Nathalie Jette, Calgary, AB, Canada, Oksana Suchowersky, Edmonton, AB, Canada, Mary Louise Myles, Edmonton, AB, Canada, Winona Wall, Calgary, AB, Canada, James Newsome, Calgary, AB, Canada, Jamie Greenfield, Calgary, AB, Canada, Marcus Koch, Calgary, AB, Canada, Scott Patten, Calgary, AB, Canada, Scott Kraft, Calgary, AB, Canada, Derek Emery, Edmonton, AB, Canada, Mayank Goyal, Calgary, AB, Canada
OBJECTIVE:
We aimed to describe the population of multiple sclerosis (MS) patients reporting chronic cerebrospinal venous insufficiency (CCSVI) treatment and to describe the change in treatment patterns and opinions over time.
BACKGROUND:
The CCSVI hypothesis has been of great interest to MS patients. Many Albertans have travelled out-of-country for venous angioplasty.
DESIGN/METHODS:
Initiated in July 2011, The Alberta Multiple Sclerosis Initiative is a longitudinal observational study that uses online questionnaires to collect patient-reported information about the safety, experiences, and outcomes following CCSVI treatment. All Albertans with MS have been encouraged to participate, irrespective of treatment status. Enrollment is ongoing.
RESULTS:
This analysis included 733 participants. Mean (SD) age was 47.9 (11.2) years, 76.5% were female, and 63.8% had relapsing remitting MS; 152 participants (20.7%; 95% CI: 17.9-23.9%) reported having CCSVI treatment, beginning in March 2010.
Participants were more likely to have undergone treatment in 2010 (66.4%; 95% CI: 58.3-73.9%, n=101) than in 2011 (30.9 %; 95% CI: 23.7-38.9%, n=47), even after controlling for the period of enrolment.
Between January and June 2012 only four participants had CCSVI treatment (2.6%; 95% CI: 0.7-6.6%).
Older age, male sex, a progressive course, and greater disability were more common in those who had CCSVI treatment.
CONCLUSIONS:
The number of participants reporting CCSVI treatment is declining. This may indicate that patients who wanted and could afford out-of-country treatment went soon after the CCSVI hypothesis was widely publicized. However, this may also reflect declining patient interest after they observed the outcomes in this earlier group of patients. The sociodemographic and clinical characteristics of participants who received CCSVI treatment will be compared to those who did not receive treatment. Factors that influenced participants' opinions for or against having CCSVI treatment will be compared over time.
Supported by: Alberta Health.
Category - MS and Related Diseases: Clinical Science
Wednesday, March 20, 2013 2:00 PM
Session P05: Multiple Sclerosis: Treatment Mechanism of Action |
|
|
| Back to top |
|
 |
|
|
You can post new topics in this forum
You can reply to topics in this forum
You can edit your posts in this forum
You can delete your posts in this forum
You cannot vote in polls in this forum
|
|
|
